LAUSR

clinically relevant and could lead to different patient management decisions in a higher proportion of patients than indicated by the authors in their original analysis. An independent study from Molino et al. [3] also undertook a comparative study of three FeNO devices. They concluded that FeNO devices are not interchangeable and that most of the disagreement was at higher FeNO values. Critically, the authors concluded that using the ATS/ERS categories comparing NIOX VERO and BV devices, there was only a 65% agreement in asthma patients. Given that both the Korn et al. and Molino et al. studies demonstrate that the BV reads higher at higher values, clinicians should carefully consider the applicability of the ERS/ATS thresholds to the device being used to monitor FeNO.